MARKET

INZY

Inozyme Pharma, Inc.
INZY
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-2.4626
-
8.11
258,247,296.00
BioMarin Raises 2025 Revenue Guidance as PALYNZIQ and VOXZOGO Sales Climb 20%
Reuters · 10/27 20:03
BioMarin updates financial impact of Inozyme Pharma acquisition with estimated 221 million charge in Q3 2025
Reuters · 10/07 21:18
BioMarin Reports Q2 2025 Revenue of $825M, GAAP EPS Up 124% Y/Y, Raises Full-Year 2025 Guidance
Reuters · 08/04 20:02
Inozyme Pharma Requests Nasdaq Delisting Post-Acquisition
TipRanks · 07/01 13:48
Press Release: BioMarin Announces Completion of Acquisition of Inozyme
Dow Jones · 07/01 12:45
*BioMarin Announces Completion Of Acquisition Of Inozyme >BMRN INZY
Dow Jones · 07/01 12:45
Weekly Report: what happened at INZY last week (0623-0627)?
Weekly Report · 06/30 09:03
Weekly Report: what happened at INZY last week (0616-0620)?
Weekly Report · 06/23 09:03
More

Webull offers Inozyme Pharma, Inc. stock information, including NASDAQ: INZY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INZY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INZY stock methods without spending real money on the virtual paper trading platform.